Market Headliners– July 7, 2025

July 7, 2025

DENVER, Colo., Jul 07, 2025 (247marketnews.com)- In a bold move to accelerate its national expansion, Venu (NYSE:VENU) appointed Terri Liebler as President of Growth and Strategy, a newly created executive role signaling the company’s intent to scale aggressively in the live entertainment space.

The appointment aligns with the launch of VENU’s Growth and Strategy division, a key milestone that emphasizes the company’s fan-first, ownership-driven model. A seasoned executive, Liebler brings over 20 years of industry experience, including a 22-year tenure at Live Nation (NYSE:LYV), where she rose to Senior Vice President of Media and Sponsorships.

“Over the past six months, as we’ve been laying the groundwork for this division, I’ve grown more and more excited about what’s ahead, and that’s in large part because of Terri Liebler,” added J.W. Roth, Founder, Chairman, and CEO of VENU.

The move strengthens VENU’s trajectory as it builds a national footprint through real estate development and PPP initiatives—targeting markets with a model that blends fan engagement and asset-backed growth.

Mustang Bio (NASDAQ:MBIO) announced that the FDA granted Orphan Drug Designation for its CAR T-cell therapy MB-101 for the treatment of recurrent astrocytomas and glioblastoma (GBM). The designation opens the door for market exclusivity and development incentives for this high-need cancer therapy.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) entered into an amended Exchange Agreement with FITTERS Diversified Berhad, an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, “Waste-To-Resource” services and real estate development and construction.

Artelo Biosciences (NASDAQ:ARTL) presented new preclinical data at the ICRS Symposium supporting the antidepressant potential of its cocrystal drug candidate ART12.11, combining cannabidiol (CBD) and tetramethylpyrazine (TMP). The 28-day study in stressed rodents showed:

  • Comparable efficacy to sertraline (Zoloft) on mood, social behavior, and pleasure
  • Superior cognitive restoration, reversing memory deficits where sertraline fell short
  • A differentiated therapeutic profile with no social memory side effects

“Our latest behavioral studies suggest that the cocrystal holds strong potential as a novel antidepressant… ART12.11 also reversed stress-induced cognitive impairments, which is an area where sertraline was not as effective,” said Matt Jones, lead researcher at the University of Western Ontario.

Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VENU, LYV, ARTL, CYCC, MBIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.